| Schlegel PN
Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. [Clinical Trial, Journal Article, Multicenter Study]
J Urol 2006 Apr; 175(4):1353-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Hirsch HJ, Gillis D, Strich D, et al.
The histrelin implant: a novel treatment for central precocious puberty. [Clinical Trial, Journal Article]
Pediatrics 2005 Dec; 116(6):e798-802.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Dineen MK, Tierney DS, Kuzma P, et al.
An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. [Clinical Trial, Phase III, Journal Article, Multicenter Study]
J Clin Pharmacol 2005 Nov; 45(11):1245-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424. [Journal Article, Review]
Drugs R D 2005; 6(1):53-5.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Fridmans A, Chertin B, Koulikov D, et al.
Reversibility of androgen deprivation therapy in patients with prostate cancer. [Journal Article]
J Urol 2005 Mar; 173(3):784-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Weise M, Flor A, Barnes KM, et al.
Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty. [Journal Article]
J Clin Endocrinol Metab 2004 Jan; 89(1):103-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Feuillan PP, Jones JV, Barnes K, et al.
Follow-up of children and young adults after GnRH-agonist therapy or central precocious puberty. [Journal Article, Review]
J Endocrinol Invest 2001 Oct; 24(9):734-6.
Full Citation | Find Related Articles | | Klein KO, Barnes KM, Jones JV, et al.
Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. [Journal Article]
J Clin Endocrinol Metab 2001 Oct; 86(10):4711-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Schlegel PN, Kuzma P, Frick J, et al.
Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin. [Clinical Trial, Journal Article]
Urology 2001 Oct; 58(4):578-82.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Chertin B, Spitz IM, Lindenberg T, et al.
An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. [Clinical Trial, Journal Article]
J Urol 2000 Mar; 163(3):838-44.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |    |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
